TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma

BACKGROUND: We previously reported that dendritic cell-based mRNA vaccination plus ipilimumab (TriMixDC-MEL IPI) results in an encouraging rate of tumor responses in patients with pretreated advanced melanoma. Here, we report the TriMixDC-MEL IPI-induced T-cell responses detected in the peripheral b...

Descripción completa

Detalles Bibliográficos
Autores principales: De Keersmaecker, Brenda, Claerhout, Sofie, Carrasco, Javier, Bar, Isabelle, Corthals, Jurgen, Wilgenhof, Sofie, Neyns, Bart, Thielemans, Kris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057443/
https://www.ncbi.nlm.nih.gov/pubmed/32114500
http://dx.doi.org/10.1136/jitc-2019-000329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057443/
https://www.ncbi.nlm.nih.gov/pubmed/32114500
http://dx.doi.org/10.1136/jitc-2019-000329

Ejemplares similares